Adlai Nortye Ltd. (ANL)
NASDAQ: ANL · Real-Time Price · USD
1.830
-0.020 (-1.08%)
May 12, 2025, 4:00 PM - Market closed
Adlai Nortye Employees
Adlai Nortye had 123 employees as of December 31, 2024. The number of employees decreased by 4 or -3.15% compared to the previous year.
Employees
123
Change (1Y)
-4
Growth (1Y)
-3.15%
Revenue / Employee
n/a
Profits / Employee
-$421,699
Market Cap
69.74M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 123 | -4 | -3.15% |
| Dec 31, 2023 | 127 | -2 | -1.55% |
| Dec 31, 2022 | 129 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ANL News
- 1 year ago - Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 - GlobeNewsWire
- 1 year ago - Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy - GlobeNewsWire
- 1 year ago - Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development - GlobeNewsWire
- 1 year ago - Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC - GlobeNewsWire
- 1 year ago - Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award - GlobeNewsWire
- 1 year ago - Adlai Nortye Dives In Nasdaq Debut, As Key Product Faces Hurdles - Seeking Alpha
- 1 year ago - Adlai Nortye Ltd. Announces Closing of Initial Public Offering - GlobeNewsWire
- 1 year ago - U.S. IPO Weekly Recap: Holdover Adlai Nortye Leads 4 IPO Week As More Small Deals Enter The Pipeline - Seeking Alpha